[HTML][HTML] Prospective iterative trial of proteasome inhibitor-based desensitization
ES Woodle, AR Shields, NS Ejaz, B Sadaka… - American Journal of …, 2015 - Elsevier
A prospective iterative trial of proteasome inhibitor (PI)-based therapy for reducing HLA
antibody (Ab) levels was conducted in five phases differing in bortezomib dosing density
and plasmapheresis timing. Phases included 1 or 2 bortezomib cycles (1.3 mg/m 2× 6–8
doses), one rituximab dose and plasmapheresis. HLA Abs were measured by solid phase
and flow cytometry (FCM) assays. Immunodominant Ab (iAb) was defined as highest HLA Ab
level. Forty-four patients received 52 desensitization courses (7 patients enrolled in multiple …
antibody (Ab) levels was conducted in five phases differing in bortezomib dosing density
and plasmapheresis timing. Phases included 1 or 2 bortezomib cycles (1.3 mg/m 2× 6–8
doses), one rituximab dose and plasmapheresis. HLA Abs were measured by solid phase
and flow cytometry (FCM) assays. Immunodominant Ab (iAb) was defined as highest HLA Ab
level. Forty-four patients received 52 desensitization courses (7 patients enrolled in multiple …